Search results for " clopidogrel"

showing 4 items of 4 documents

Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent…

2012

This study aimed to assess if proton pump inhibitors (PPIs) may reduce the effectiveness of clopidogrel, than H2 antagonist (anti-H2) in order to determine rehospitalization for acute coronary syndrome (re-ACS), target vessel revascularization (TVR) and cardiac death. This case-control study included 176 patients with ACS undergoing angioplasty (PCI) with drug-eluting stent implantation. The population was divided into two groups: PPI group (n=121) consisting of patients receiving at discharge dual antiplatelet therapy (DAT) plus PPI and anti-H2 group (n=55), consisting of patients receiving at discharge DAT + H2 receptor antagonist (H2RA). In a followup of 36 months the prevalence of ACS e…

Acute coronary syndromemedicine.medical_specialtyeducation.field_of_studyArticle Subjectbusiness.industrymedicine.medical_treatmentPopulationmedicine.diseaseClopidogrelEsomeprazoleSurgeryantiplatelet therapy PPIs clopidogrel anti-H2 ACS PCIDrug-eluting stentInternal medicineAngioplastyConventional PCImedicineCardiologyClinical StudyeducationbusinessOmeprazolemedicine.drug
researchProduct

LE VARIANTI DEL GENE CYP2C19 NELLA FARMACO-GENOMICA DEL CLOPIDOGREL

2010

Il clopidogrel per espletare la propria funzione di antiaggregante piastrinica necessita l’intervento di diversi citocromi epatici. Le varianti del gene CYP2C19 sembrano influenzarne sensibilmente l’attivazione e pertanto l’azione farmacologica. Sono stati identificati tre alleli principali. L’allele CYP2C19*1 è il wild type e codifica per un enzima costituzionalmente attivo. Gli alleli CYP2C9*2 e CYP2C9*3 codificano invece per forme enzimatiche parzialmente funzionanti e sono responsabili sia in eterozigosi che in omozigosi della variazione di attività farmacologica. La valutazione delle varianti è stata eseguita mediante le metodiche PCR-RFLP e sequenziamento diretto. Abbiamo allestito du…

CYP2C19 farmacogenomica clopidogrelSettore BIO/14 - Farmacologia
researchProduct

Tendencia en la utilización de antiagregantes en la Comunidad Valenciana (2000-2005)

2007

Beatriz Román Llamosí, Rocío Broseta Solaz, Joan Quiles Izquierdo y Amalia Úbeda Pascual (Amalia.Ubeda@uv.es) Los antiagregantes plaquetarios son fármacos básicos para la prevención de enfermedades isquémicas arteriales. El objetivo de este trabajo es conocer la evolución de su utilización en Atención Primaria en la Comunidad Valenciana durante el periodo 2000-2005. Métodos: Estudio descriptivo del consumo de los antiagregantes plaquetarios (código ATC: B01AC) dispensados con cargo al Sistema Nacional de Salud en la Comunidad Valenciana en el ámbito de Atención Primaria. Datos expresados en dosis diarias definidas (DDD) por 1.000 habitantes y día. Resultados: En 2005 tres fármacos represent…

Drugmedicine.medical_specialtyArterial diseasemedia_common.quotation_subjectlcsh:MedicinePrimary careUNESCO::CIENCIAS MÉDICAS ::Salud públicaInternal medicineAntiagregantes plaquetarios:CIENCIAS MÉDICAS ::Salud pública [UNESCO]MedicineUtilización de medicamentosmedia_commonNational healthbusiness.industryIncidence (epidemiology)lcsh:Public aspects of medicineÁcido acetilsalicícicolcsh:Rlcsh:RA1-1270General MedicineClopidogrelClopidogrelSurgeryPlatelet aggregation inhibitorTriflusalbusinessAntiagregantes plaquetarios; Clopidogrel; Ácido acetilsalicícico; Utilización de medicamentosmedicine.drug
researchProduct

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor
researchProduct